Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Larger Is The Drug Eluting Balloons Catheters Market Expected To Become By 2029 Compared With Its 2025 Level?
The sphere of drug-eluting balloon catheters has experienced swift expansion lately; projections indicate a rise from $1.43 billion in 2024 to $1.65 billion in 2025, reflecting a compounded annual growth rate totaling 15.4%. This historical upward trend is propelled by several factors, including the prevalence of respiratory ailments, the benefits these catheters offer compared to older inhaler methods, increased patient acceptance of dpis, supportive governmental programs focused on respiratory wellness, strategic alliances forged between entities, enhancements in how drugs are prepared, and the aging demographic’s growth.
Forecasting indicates that the drug-eluting balloon catheters sector is poised for substantial expansion in the approaching years, projected to reach a valuation of $2.62 billion by 2029, reflecting a compound annual growth rate of 12.2%. This upward trajectory throughout the forecasted timeframe stems from several key factors such as the persistent rise in respiratory ailments, the expanding segment of the elderly population, heightened levels of awareness and patient education, penetration into nascent global markets, development of personalized drug compositions, supportive regulatory frameworks, and advancements in the physical packaging and structural configuration of the devices. Significant shifts observed during this period are characterized by the integration of smart inhaler technology with connectivity features, a movement favoring inhalers activated purely by the patient’s breath, increased attention directed towards the specific requirements of pediatric and elderly users, the incorporation of biologics for therapeutic delivery, and a growing emphasis on creating inhalation device models that are more ecologically sustainable.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13429&type=smp
Which Drivers Are Supporting Growth Of The Drug Eluting Balloons Catheters Market?
The increasing incidence of both peripheral and cardiovascular ailments is anticipated to fuel the expansion of the market for drug-eluting balloon catheters in the future; these cardiovascular conditions affect the heart and vascular network, while peripheral artery disease specifically involves constricted arteries diminishing blood circulation, predominantly in the limbs, and drug-eluting balloon catheters serve as an intervention for coronary artery disease, utilizing a semi-compliant angioplasty balloon impregnated with an anti-proliferative agent designed to exert an anti-restenotic influence upon deployment within the vessel, as exemplified by data shared in May 2024 from the US government agency, the Centers for Disease Control and Prevention, indicating that heart disease was responsible for 702,880 fatalities in 2022, representing one fifth of all deaths, and furthermore, roughly 805,000 individuals in the United States suffer a heart attack annually, with 605,000 being initial occurrences and 200,000 happening to those with a prior history, consequently highlighting that the escalating rate of these vascular and cardiac diseases is the impetus behind the market growth for drug-eluting balloon catheters.
What Are The Segment Types Shaping The Drug Eluting Balloons Catheters Market?
The drug eluting balloons cathetersmarket covered in this report is segmented –
1) By Product: Coronary Artery Disease Drug-Eluting Balloon Catheters, Peripheral Vascular Disease Drug-Eluting Balloon Catheters
2) By Drug: Paclitaxel, Sirolimus, Other Drugs
3) By Raw Material: Nylon, Polyurethane, Other Raw Materials
4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Catheterization Laboratories
Subsegments:
1) By Coronary Artery Disease: Drug-Eluting Balloon Catheters, Plain Balloon Catheters
2) By Peripheral Vascular Disease: Drug-Eluting Balloon Catheters, Angioplasty Balloon Catheters
3) By Angioplasty Balloon Catheters: Drug-Eluting Angioplasty Balloon Catheters
How Are Trends Influencing The Drug Eluting Balloons Catheters Market?
To secure a stronger position within the drug-eluting balloon catheter marketplace, leading corporations are heavily concentrating resources on innovating next-generation devices incorporating cutting-edge capabilities. Illustratively, in March of 2024, Boston Scientific Corporation, a major American corporation renowned for its biomedical engineering and global medical device production, publicized that the U.S. Food and Drug Administration (FDA) had granted clearance for its AGENT Drug-Coated Balloon (DCB). This AGENT DCB represents a significant milestone as the inaugural coronary balloon coated with medication to be authorized within the United States specifically for managing in-stent restenosis (ISR), a condition involving the re-obstruction of a stented artery by accumulated plaque or fibrous tissue. The device utilizes a paclitaxel application to administer a therapeutic quantity of medication directly onto the vessel lining, effectively mitigating the likelihood of ISR returning without necessitating further stent placement or the use of radiation therapy; data from clinical investigations pointed towards a 49 percent reduction in heart attack occurrences at the targeted location alongside impressively low frequencies of undesirable patient outcomes.
Which Leading Players Are Enhancing Their Drug Eluting Balloons Catheters Market Presence Worldwide?
Major companies operating in the drug eluting balloons catheters market report are Abbott Laboratories, Medtronic PLC, Becton Dickinson and Company, Koninklijke Philips NV, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, Cook Medical LLC, Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Mermaid Medical AS, Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Machine Solutions Inc., Concept Medical Inc., Aachen Resonance GmbH, AR Baltic Medical UAB
Download The Full Report For Exclusive Market Findings:
Which Region Shows The Highest Potential For Future Expansion In The Drug Eluting Balloons Catheters Market?
North America was the largest region in the drug eluting balloons catheters market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Drug Eluting Balloons Catheters Market Report:
https://www.thebusinessresearchcompany.com/customise?id=13429&type=smp
Browse Through More Reports Similar to the Global Drug Eluting Balloons Catheters Market 2025, By The Business Research Company
Narcotic Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/narcotic-drugs-global-market-report
Focal Segmental Glomerulosclerosis Drugs Global Market Report 2025
Antiparasitic Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antiparasitic-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model